The estimated Net Worth of Charles M Baum is at least $20.5 Million dollars as of 4 January 2023. Charles Baum owns over 3,648 units of Mirati Therapeutics Inc stock worth over $9,907,210 and over the last 11 years he sold MRTX stock worth over $2,094,408. In addition, he makes $8,484,390 as President, Chief Executive Officer, and Director at Mirati Therapeutics Inc.
Charles has made over 32 trades of the Mirati Therapeutics Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently he sold 3,648 units of MRTX stock worth $169,997 on 4 January 2023.
The largest trade he's ever made was exercising 69,256 units of Mirati Therapeutics Inc stock on 28 November 2022 worth over $1,205,747. On average, Charles trades about 10,441 units every 51 days since 2013. As of 4 January 2023 he still owns at least 168,777 units of Mirati Therapeutics Inc stock.
You can see the complete history of Charles Baum stock trades at the bottom of the page.
Dr. Charles M. Baum M.D., Ph.D. serves as President, Chief Executive Officer, Director of the Company. He has served as our President and Chief Executive Officer and member of our Board of Directors since November 2012. From June 2003 to September 2012, he was at Pfizer as Senior Vice President for Biotherapeutic Clinical Research within Pfizer's Worldwide Research & Development division and as Vice President and Head of Oncology Development and Chief Medical Officer for Pfizer's Biotherapeutics and Bioinnovation Center. From 2000 to 2003, he was responsible for the development of several oncology compounds at Schering-Plough Corporation (acquired by Merck). His career has included academic and hospital positions at Stanford University and Emory University, as well as positions of increasing responsibility within the pharmaceutical industry at SyStemix, Inc. (acquired by Novartis AG), G.D. Searle & Company (acquired by Pfizer), Schering-Plough Corporation (acquired by Merck) and Pfizer. Dr. Baum currently serves on the board of directors of Immunomedics, Inc. and was on the board of directors of Array BioPharma Inc. from 2014 until its acquisition by Pfizer in July 2019. Dr. Baum received his M.D. and Ph.D. (Immunology) degrees from Washington University School of Medicine in St. Louis, Missouri and completed his post-doctoral training at Stanford University.
As the President, Chief Executive Officer, and Director of Mirati Therapeutics Inc, the total compensation of Charles Baum at Mirati Therapeutics Inc is $8,484,390. There are no executives at Mirati Therapeutics Inc getting paid more.
Charles Baum is 62, he's been the President, Chief Executive Officer, and Director of Mirati Therapeutics Inc since 2012. There are 3 older and 14 younger executives at Mirati Therapeutics Inc. The oldest executive at Mirati Therapeutics Inc is Bruce Carter, 76, who is the Independent Director.
Charles's mailing address filed with the SEC is C/O POSEIDA THERAPEUTICS, INC., 9390 TOWNE CENTER DRIVE SUITE 200, SAN DIEGO, CA, 92121.
Over the last 11 years, insiders at Mirati Therapeutics Inc have traded over $179,669,845 worth of Mirati Therapeutics Inc stock and bought 8,779,906 units worth $186,410,608 . The most active insiders traders include Healthcare Master Fund Ltd ..., Capital Advisors Llc Aghaza..., and Bros. Advisors Lp Baker Bro.... On average, Mirati Therapeutics Inc executives and independent directors trade stock every 22 days with the average trade being worth of $5,885,145. The most recent stock trade was executed by Benjamin Hickey on 16 January 2024, trading 1,597 units of MRTX stock currently worth $94,255.
mirati therapeutics develops molecularly targeted, single agent and immuno-oncology combination therapies intended to treat cancer. mirati's approach combines the three most important factors in oncology drug development, 1) researching and developing drug candidates that target genetic and epigenetic drivers of cancer, 2) designing creative and agile clinical development strategies that select for patients whose tumors are dependent on specific driver alterations, and 3) leveraging a highly accomplished oncology precision medicine leadership team. the mirati team uses a blueprint – proven by their prior work – for developing potential breakthrough cancer therapies, with accelerated development paths, in order to improve outcomes for patients. mirati is advancing three drug candidates through clinical development for multiple oncology indications.
Mirati Therapeutics Inc executives and other stock owners filed with the SEC include: